Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Topline Section 3 outcomes present Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight reduction in adults with kind 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus only one hit by Ozempic.

The publish Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Kind 2 Diabetes Trial appeared first on MedCity Information.

Source link